BioLargo, Inc. Files 8-K Report
Ticker: BLGO · Form: 8-K · Filed: Nov 18, 2025 · CIK: 880242
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
BioLargo filed an 8-K on 11/14/25. Check it for updates.
AI Summary
On November 14, 2025, BioLargo, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Nuway Medical Inc., is incorporated in Delaware and headquartered in Westminster, California.
Why It Matters
This filing provides an update on BioLargo, Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report with no immediately apparent negative or positive financial events disclosed.
Key Players & Entities
- BioLargo, Inc. (company) — Registrant
- Nuway Medical Inc. (company) — Former company name
- November 14, 2025 (date) — Date of earliest event reported
- 14921 Chestnut St. (address) — Principal executive offices
- Westminster, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for BioLargo, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 14, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 14, 2025.
What is BioLargo, Inc.'s principal executive office address?
BioLargo, Inc.'s principal executive office is located at 14921 Chestnut St., Westminster, California 92683.
What were some of BioLargo, Inc.'s former company names?
BioLargo, Inc. was formerly known as Nuway Medical Inc., Nuway Energy Inc., and Latin American Casinos Inc.
In which state is BioLargo, Inc. incorporated?
BioLargo, Inc. is incorporated in Delaware.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-11-17 20:19:45
Key Financial Figures
- $99,901 — rgo Inc. agreed to convert an aggregate $99,901 of unpaid salary and unreimbursed busin
- $0.16 — 's common stock on November 14, 2025 of $0.16. An aggregate 624,383 shares were issue
- $40 million — Inc. reports gross revenue of at least $40 million on a consolidated basis for any reporte
- $300 m — ), or its market capitalization exceeds $300 million, or it undergoes a "change in con
Filing Documents
- blgo20251117_8k.htm (8-K) — 28KB
- ex_889888.htm (EX-10.1) — 15KB
- 0001437749-25-035506.txt ( ) — 172KB
- blgo-20251117.xsd (EX-101.SCH) — 3KB
- blgo-20251117_def.xml (EX-101.DEF) — 11KB
- blgo-20251117_lab.xml (EX-101.LAB) — 14KB
- blgo-20251117_pre.xml (EX-101.PRE) — 11KB
- blgo20251117_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 14, 2025, two officers of BioLargo Inc. agreed to convert an aggregate $99,901 of unpaid salary and unreimbursed business expenses into shares of BioLargo Inc. common stock at a price-per-share equal to the closing price of BioLargo's common stock on November 14, 2025 of $0.16. An aggregate 624,383 shares were issued to the two officers. The shares issued are subject to a Lock-Up Agreement dated as of the issuance date whereby the shares are locked-up and restricted from sale until BioLargo Inc. reports gross revenue of at least $40 million on a consolidated basis for any reported period (e.g, quarter or annual), or its market capitalization exceeds $300 million, or it undergoes a "change in control".
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Lock-Up Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 17, 2025 BIOLARGO, INC. By: /s/ Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer